Title
Recommendations for Prevention and Control of Influenza in Children, 2023–2024
Authoring Organization
Publication Month/Year
August 29, 2023
Last Updated Month/Year
September 6, 2023
Supplemental Implementation Tools
Document Type
Consensus
Country of Publication
US
Document Objectives
This statement updates the recommendations of the American Academy of Pediatrics for the routine use of influenza vaccine and antiviral medications in the prevention and treatment of influenza in children during the 2023–2024 influenza season. The American Academy of Pediatrics recommends annual influenza vaccination of all children without medical contraindications starting at 6 months of age. Children are at risk for hospitalization and death from influenza. Influenza vaccination is an important strategy for protecting children and the broader community, as well as reducing the overall burden of respiratory illnesses when other viruses are cocirculating. Any licensed influenza vaccine appropriate for age and health status can be administered, ideally as soon as possible in the season, without preference for one product or formulation over another.
Target Patient Population
Children and adolescents who have influenza and/or who may be eligible to receive influenza vaccinations
Target Provider Population
Pediatricians and other clinicians caring for children
Inclusion Criteria
Male, Female, Adolescent, Child, Infant
Health Care Settings
Ambulatory, Childcare center, School
Intended Users
Nurse, nurse practitioner, physician, physician assistant
Scope
Treatment, Prevention
Diseases/Conditions (MeSH)
D007252 - Influenza Vaccines, D007251 - Influenza, Human
Keywords
influenza, influenza vaccines, pediatric influenza, pediatric vaccines
Source Citation
COMMITTEE ON INFECTIOUS DISEASES; Recommendations for Prevention and Control of Influenza in Children, 2023–2024. Pediatrics 2023; e2023063772. 10.1542/peds.2023-063772